GES-13, a β-Lactamase Variant Possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa
- 1 March 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (3) , 1331-1333
Abstract
GES-13 β-lactamase, a novel GES variant possessing Lys-104 and Asn-170, was identified in Pseudomonas aeruginosa. bla GES-13 was the single gene cassette of a class 1 integron probably located in the chromosome. GES-13 efficiently hydrolyzed broad-spectrum cephalosporins and aztreonam. Imipenem was a potent inhibitor of GES-13 but was not hydrolyzed at measurable rates.Keywords
This publication has 17 references indexed in Scilit:
- GES-11, a Novel Integron-Associated GES Variant in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2009
- Relative Strengths of the Class 1 Integron Promoter Hybrid 2 and the Combinations of Strong and Hybrid 1 with an Active P2 PromoterAntimicrobial Agents and Chemotherapy, 2009
- Genetic support of extended-spectrum β-lactamasesClinical Microbiology and Infection, 2008
- Minor extended-spectrum β-lactamasesClinical Microbiology and Infection, 2008
- Biochemical and Molecular Characterization of Three New Variants of AmpC β-Lactamases from Morganella morganiiAntimicrobial Agents and Chemotherapy, 2006
- Integron-Encoded GES-Type Extended-Spectrum β-Lactamase with Increased Activity toward Aztreonam in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2005
- Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A β-Lactamase, GES-4, Possessing a Single G170S Substitution in the Ω-LoopAntimicrobial Agents and Chemotherapy, 2004
- Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteriaFEMS Microbiology Letters, 2004
- Novel GES/IBC extended-spectrum ?-lactamase variants with carbapenemase activity in clinical enterobacteriaFEMS Microbiology Letters, 2004
- Biochemical Sequence Analyses of GES-1, a Novel Class A Extended-Spectrum β-Lactamase, and the Class 1 Integron In52 from Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2000